Aloe polysaccharides, particularly acemannan and other mannose-rich compounds, have been investigated for their potential hepatoprotective and immunomodulatory effects in the context of hepatitis. Preclinical studies, mostly in animal models and in vitro systems, suggest that Aloe polysaccharides can reduce markers of liver inflammation, oxidative stress, and viral replication in hepatitis models. For example, some studies in rodents with chemically induced hepatitis found that Aloe vera extracts (rich in polysaccharides) reduced liver enzyme levels and improved histopathological features. Limited in vitro data also indicate that Aloe polysaccharides may inhibit hepatitis virus activity and modulate immune responses.

However, high-quality human clinical trials are lacking, and the existing human data are sparse and not definitive. The evidence thus far is mostly experimental and does not provide strong clinical validation for the use of Aloe polysaccharides as a treatment for hepatitis in humans. The traditional use of Aloe for liver conditions exists in some herbal medicine systems, but is not as prominent as its use for skin or digestive issues. Therefore, while there is some scientific rationale and preliminary evidence, it is not yet robust or conclusive, which is reflected in the moderate evidence rating.